Clinical, Cosmetic and Investigational Dermatology (Jan 2024)
Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review
Abstract
Pingjiao Chen,1,* Jingyao Liang,2,3,* Changxing Li,1 Qian Li,2,3 Wenyan Liu,2,3 Junhui Zhu,2,3 Weifeng Chen,2,3 Xibao Zhang2,3 1Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China; 2Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People’s Republic of China; 3Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xibao Zhang, Department of Dermatology Guangzhou Institute of Dermatology, 56 Hengfu Road, Guangzhou, 510095, People’s Republic of China, Tel +8620-83593476, Email [email protected]: Janus kinase (JAK) inhibitors are increasingly being used in dermatology due to their broad potential in managing both local and systemic inflammation. More recently, abrocitinib, an oral JAK 1 inhibitor, has shown promising clinical efficacy in the treatment of various skin disorders beyond moderate to severe atopic dermatitis (AD). We firstly presented three cases, each with diagnosis of pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS), and conducted a comprehensive scoping review of the available literature on the use of abrocitinib in the treatment of diverse skin disorders. We summarized a total of 16 skin disorders, including our cases. The results indicated that abrocitinib, whether used as monotherapy or in combination with other treatments, was effective and well-tolerated in these disorders. These findings expanded the range of diseases for which abrocitinib may serve as an alternative therapeutic choice.Keywords: JAK inhibitors, abrocitinib, atopic dermatitis, pyoderma gangrenosum, livedoid vasculopathy, hidradenitis suppurativa
